These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 27184564)

  • 1. Advances in antibiotic therapy in the critically ill.
    Vincent JL; Bassetti M; François B; Karam G; Chastre J; Torres A; Roberts JA; Taccone FS; Rello J; Calandra T; De Backer D; Welte T; Antonelli M
    Crit Care; 2016 May; 20(1):133. PubMed ID: 27184564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients?
    Eachempati SR; Hydo LJ; Shou J; Barie PS
    J Trauma; 2009 May; 66(5):1343-8. PubMed ID: 19430237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individualized antibiotic strategies.
    Taccone FS; Bond O; Cavicchi FZ; Hites M
    Curr Opin Anaesthesiol; 2016 Apr; 29(2):166-71. PubMed ID: 26765979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic issues for antibiotics in the critically ill patient.
    Roberts JA; Lipman J
    Crit Care Med; 2009 Mar; 37(3):840-51; quiz 859. PubMed ID: 19237886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to optimize antibiotic pharmacokinetic/pharmacodynamics for Gram-negative infections in critically ill patients.
    Heffernan AJ; Sime FB; Taccone FS; Roberts JA
    Curr Opin Infect Dis; 2018 Dec; 31(6):555-565. PubMed ID: 30299354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use and risks of antibiotics in critically ill patients.
    Denny KJ; Cotta MO; Parker SL; Roberts JA; Lipman J
    Expert Opin Drug Saf; 2016 May; 15(5):667-78. PubMed ID: 26961691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of beta-lactam antibiotics in critically ill patients.
    Sulaiman H; Roberts JA; Abdul-Aziz MH
    Farm Hosp; 2022 Mar; 46(3):182-190. PubMed ID: 36183212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. To which extent can we decrease antibiotic duration in critically ill patients?
    Garnacho-Montero J; Arenzana-Seisdedos A; De Waele J; Kollef MH
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1215-1223. PubMed ID: 28837364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics in critically ill patients.
    Varghese JM; Roberts JA; Lipman J
    Curr Opin Anaesthesiol; 2010 Aug; 23(4):472-8. PubMed ID: 20489605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy?
    Jamal JA; Mueller BA; Choi GY; Lipman J; Roberts JA
    Diagn Microbiol Infect Dis; 2015 May; 82(1):92-103. PubMed ID: 25698632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Simulation Study Reveals Lack of Pharmacokinetic/Pharmacodynamic Target Attainment in De-escalated Antibiotic Therapy in Critically Ill Patients.
    Carlier M; Roberts JA; Stove V; Verstraete AG; Lipman J; De Waele JJ
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4689-94. PubMed ID: 26014946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute exacerbations of chronic obstructive pulmonary disease: diagnosis, management, and prevention in critically ill patients.
    Dixit D; Bridgeman MB; Andrews LB; Narayanan N; Radbel J; Parikh A; Sunderram J
    Pharmacotherapy; 2015 Jun; 35(6):631-48. PubMed ID: 26032691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antibiotics in the critically ill].
    Kolak RR
    Med Pregl; 2010; 63 Suppl 1():27-32. PubMed ID: 21438201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ampicillin/sulbactam: its potential use in treating infections in critically ill patients.
    Adnan S; Paterson DL; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2013 Nov; 42(5):384-9. PubMed ID: 24041466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pros and cons of using biomarkers versus clinical decisions in start and stop decisions for antibiotics in the critical care setting.
    Albrich WC; Harbarth S
    Intensive Care Med; 2015 Oct; 41(10):1739-51. PubMed ID: 26194026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing use of beta-lactam antibiotics in the critically ill.
    Roberts JA; Lipman J
    Semin Respir Crit Care Med; 2007 Dec; 28(6):579-85. PubMed ID: 18095221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing dosing of antibiotics in critically ill patients.
    Parker SL; Sime FB; Roberts JA
    Curr Opin Infect Dis; 2015 Dec; 28(6):497-504. PubMed ID: 26382000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of extended-interval aminoglycoside dosing strategies for the treatment of moderate-to-severe infections encountered in critically ill surgical patients.
    Mueller EW; Boucher BA
    Surg Infect (Larchmt); 2009 Dec; 10(6):563-70. PubMed ID: 20035611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility.
    Roberts JA; Lipman J
    Crit Care Med; 2013 Feb; 41(2):489-95. PubMed ID: 23263583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibiotic dose optimization in critically ill patients.
    Cotta MO; Roberts JA; Lipman J
    Med Intensiva; 2015 Dec; 39(9):563-72. PubMed ID: 26415688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.